ArticleLancet regional health. Americas2022
Overdose deaths involving non-BZD hypnotic/sedatives in the USA: Trends analyses.
Article in Lancet regional health. Americas, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Sleep Medication Use and Associated Factors Among Adults with Insomnia Symptoms: A Cross-Sectional Study in Brazil.Sleep science (Sao Paulo, Brazil) · 2026Article
- Comparative pharmacovigilance of non-benzodiazepine receptor agonists versus dual orexin receptor antagonists for insomnia in older adults.Frontiers in pharmacology · 2026Article
- High-dose use of pregabalin and gabapentin in France: a retrospective, population-based cohort study.The Lancet regional health. Europe · 2025Article
- Evaluation of a hospital-based opioid stewardship program on high-risk opioid prescribing in a Canadian setting: an interrupted time series analysis.Addiction science & clinical practice · 2025Article
- Nationwide trends in diagnosed sedative, hypnotic or anxiolytic use disorders in adolescents and young adults enrolled in Medicaid: 2001-2019.Addiction (Abingdon, England) · 2025Article
- Substance use and traumatic events among Afghan general population: findings from the Afghanistan national mental health survey.BMC psychiatry · 2025Article
- A qualitative study of benzodiazepine/z-drug and opioid co-use patterns and overdose risk.Harm reduction journal · 2025Article
- Temporal stability and volatility in population-level high-risk illicit polysubstance use by gender and marital status in the United States, 2002-2019.Social science & medicine (1982) · 2025Article
- Incident gabapentin prescribing associated with opioid and benzodiazepine/Z-drug prescribing - a population-based longitudinal study in primary care.Frontiers in pharmacology · 2025Article
- The role of prescribed controlled substance acquisition as potential triggers of opioid overdose: A case-crossover study.The International journal on drug policy · 2024Article
- Characterising incident opioid use among incident users of prescription sedative hypnotics: A national cohort study.BMJ open · 2024Article
- Death after smoking of fentanyl, 5F-ADB, 5F-MDMB-P7AICA and other synthetic cannabinoids with a bucket bong.Forensic toxicology · 2024Article
- Association between prescription drug monitoring programs use mandates and prescription stimulants received by Medicaid enrollees.Drug and alcohol review · 2023Article
- Trends in overdose deaths involving gabapentinoids and Z-drugs in the United States.Drug and alcohol dependence · 2023Article
- Prescription drug monitoring programs use mandates and prescription stimulant and depressant quantities.BMC public health · 2023Article
- Sleep-promoting activity of amylase-treated Ashwagandha (Withania somnifera L. Dunal) root extract via GABA receptors.Journal of food and drug analysis · 2023Article
- Occurrence of Z-drugs, benzodiazepines, and ketamine in wastewater in the United States and Mexico during the Covid-19 pandemic.The Science of the total environment · 2023Article
- Balancing Risk and Uncertain Benefit in Pharmacotherapy for Pain in Kidney Transplant Recipients.Clinical journal of the American Society of Nephrology : CJASN · 2023Article
- Gabapentinoid-related deaths: An alarming global trend or just a special challenge within the long tail of the giant opioid epidemic?Lancet regional health. Americas · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is sparse knowledge on overdose deaths resulting from non-benzodiazepines and gabapentinoids usage. We examined overdose death rate across demographics categories and the overdose death trends over time. Methods: Using data from the National Center for Health Statistics (USA), we identified 21,167 persons that died with an overdose ICD code as the underlying cause of death and had a T42.6/T42.7 ICD code, which include gabapentinoids and z-drugs, among their multiple causes of death. The overdose death rate was calculated per 100,000 persons for every year between 2000 and 2018. We used joinpoint regression analyses to assess trends over time. Results: We identified a rise in the proportion of deaths with a T42.6/T42.7 ICD code between 2000 and 2006 (yearly change: +0.06) and between 2006 and 2015 (yearly change: +0.32). From 2000 to 2008, the proportion of deaths with any other T code rose significantly (yearly change: +3.56). Between 2008 and 2018, there was also a significant rise (yearly change: +1.31). From 2000 to 2015, the proportion of deaths with a T42.6/T42.7 ICD code with any other T code rose (yearly change: +2.58). From 2000 to 2015, the proportion of deaths with a T42.6/T42.7 ICD code with a concurrent benzodiazepine T code rose (yearly change: +1.98). From 2000 to 2005, the proportion of alcohol T codes rose non-significantly (yearly change: +0.35). Finally, the proportion of alcohol T codes fell significantly between 2008 and 2018 (yearly change: - 0.74). Interpretation: Deaths due to non-benzodiazepine hypnotics and gabapentinoids increased significantly over the last two decades. Clinicians should not assume that replacing benzodiazepines and opioids with these medications necessarily lowers risk to the patient. Funding: This study was funded by an internal grant from the Columbia University President's Global Innovation Fund (PI: Martins).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.